NSE: INDGN | BSE: 544172

Mid-range Performer

Download real time

581.60 -14.10 (-2.37%)

1.8M NSE+BSE Volume

High vol. this week

NSE 06 Jun, 2025 3:31 PM (IST)

13,959

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Block Deal

Carlyle Group to divest its entire 10.2% stake in Indegene for Rs 1,420 crore via a block deal See details

Indegene Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDGN, BSE:544172 Indegene Ltd.

Search Inside the pdf :

Indegene Ltd.

10 Jul 2024

581.60

-2.37%

Indegene Limited - Revolutionizing Life Sciences' Marketing Way

Buy: Indegene Ltd.

Monarch Networth Capital Limited

Number of FII/FPI investors increased from 102 to 114 in Mar 2025 qtr.

Indegene Ltd.

06 May 2024, 12:00AM

581.60

-2.37%

Indegene provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. The Company has established client relationships with each of the 20 largest biopharmaceutical companies in the world.

Indegene Ltd. has an average target of 660.00 from 1 broker.

Indegene Ltd.

03 May 2024

581.60

-2.37%

IPO Note - Indegene Limited 06052024

IPO Note: Indegene Ltd.

HDFC Securities

IPO Note - Indegene Limited Indegene Limited (IL) provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products